• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax

    12/20/22 9:00:00 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GOVX alert in real time by email

    First Woman President and CEO of MSM and Internationally Recognized Health Equity Advocate Joins in GeoVax Special Advisory Role

    ATLANTA, GA, Dec. 20, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today the appointment of Valerie Montgomery Rice, MD, FACOG, Morehouse School of Medicine President and CEO, as Special Advisor to the Chairman/CEO and Board of Directors of GeoVax.

    Dr. Montgomery Rice brings GeoVax exceptional expertise and highly recognized experience at the highest levels of healthcare leadership, patient care, biomedical research, and public health policy.

    "We are delighted Dr. Montgomery Rice is joining in this unique advisory role for GeoVax's growing ecosystem of outstanding executives, advisors, board members, scientists, and partners," said David Dodd, GeoVax Chairman and CEO. "Her organizational management acumen and career-long dedication to advance medical training, health equity and other critical areas of public health, will add dimension to our initiatives to expand access to our investigational vaccines and immunotherapies against life-threatening infectious diseases and cancers."  

    Dr. Montgomery Rice has been a driving force behind research, education and care that closes equity gaps in healthcare, including women's health. She currently serves as President and Chief Executive Officer of the Morehouse School of Medicine (MSM) in Atlanta and is the first woman in the institution's history to serve in this role. At MSM, she has also served as Dean and Executive Vice President and professor of Obstetrics and Gynecology. Prior to MSM, Dr. Montgomery Rice held a number of faculty and leadership positions at Meharry Medical College in Nashville, including professor and chair in the Department of Obstetrics and Gynecology, Dean and Senior Vice President of Meharry Medical College's School of Medicine, and Program Director of the OB-GYN Residency Training Program and Founding Director of the Center for Women's Health Research, one of the nation's first research centers devoted to studying diseases that disproportionately impact women of color. Dr. Montgomery Rice also served in faculty and leadership roles at University of Kansas School of Medicine, Vanderbilt University Medical Center, and Henry Ford Medical Center.

    Dr. Montgomery Rice holds memberships in various organizations and participates on several boards. She is an Advisory Board Member of the Historically Black Colleges and Universities Capital Financing Advisory Board. She also serves on the board of directors for UnitedHealth Group, Wellpath, 23&Me, Nemours, CARE USA, Josiah Macy Jr. Foundation, and the Moffit Cancer Center. In 2021, Governor Brian Kemp appointed Dr. Montgomery Rice to the Georgia Commission on Women, where she lends her depth of knowledge and expertise as a women's health researcher to improve the life of women and their families in Georgia. In March 2022, President Joe Biden appointed Dr. Montgomery Rice to the President's Committee on the National Medal of Science.

    "I am particularly excited about GeoVax's innovative programs focused on providing the public protection from the most pressing and emerging infectious disease threats," said Dr. Montgomery Rice. "I look forward to helping GeoVax as the company progresses its vaccine and immunology programs toward patients."

    Dedicated to the creation and advancement of health equity, Dr. Montgomery Rice's career has been recognized with numerous accolades and honors, notably, the Horatio Alger Award, the National Human Relations Award from the American Jewish Committee Atlanta, the Dean Griffin Community Service Award from the Georgia Institute of Technology, Girls Inc. 2019 Smart Award, the National Medical Association OB/GYN 2019 Legend of the Section Award, the Turknett Leadership Character Award, Visions of Excellence Award from the Atlanta Business League, the Links Incorporated Co-Founders Award, the Trumpet Vanguard Award, the Dorothy I. Height Crystal Stair Award, National Coalition of 100 Black Women - Women of Impact, YWCA – Women of Achievement of Atlanta and Nashville, American Medical Women's Association Elizabeth Blackwell Medal, and Working Mother Media Multicultural Women's Legacy Award. 

    Dr. Montgomery Rice holds a bachelor's degree in chemistry from the Georgia Institute of Technology, a medical degree from Harvard Medical School, an honorary degree from the University of Massachusetts Medical School, and a Doctor of Humane Letters honorary degree from Rush University.

    About GeoVax

    GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for cancers and many of the world's most threatening infectious diseases. The company's lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax's lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine targeting high-risk immunocompromised patient populations. Currently in two Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a single-dose, COVID-19 vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient. In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information, visit our website: www.geovax.com.

    Media Relations Contact:

    Gina Cestari

    6 Degrees

    917-797-7904 

    [email protected]

    Investor Relations Contact:

    Rich Cockrell

    CG Capital

    404-736-3838 

    [email protected]



    Primary Logo

    Get the next $GOVX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GOVX

    DatePrice TargetRatingAnalyst
    4/15/2025$18.00 → $14.00Buy
    D. Boral Capital
    4/15/2025$15.00 → $8.50Buy
    Alliance Global Partners
    11/11/2024$15.00Buy
    Alliance Global Partners
    7/16/2024$20.00Buy
    ROTH MKM
    More analyst ratings

    $GOVX
    SEC Filings

    See more
    • SEC Form 424B3 filed by GeoVax Labs Inc.

      424B3 - GeoVax Labs, Inc. (0000832489) (Filer)

      5/1/25 5:08:24 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by GeoVax Labs Inc.

      424B3 - GeoVax Labs, Inc. (0000832489) (Filer)

      5/1/25 5:06:58 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by GeoVax Labs Inc.

      424B3 - GeoVax Labs, Inc. (0000832489) (Filer)

      5/1/25 5:05:25 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOVX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by GeoVax Labs Inc.

      SC 13G/A - GeoVax Labs, Inc. (0000832489) (Subject)

      11/14/24 5:10:48 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by GeoVax Labs Inc.

      SC 13G - GeoVax Labs, Inc. (0000832489) (Subject)

      2/14/24 3:38:25 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - GeoVax Labs, Inc. (0000832489) (Subject)

      2/10/21 3:16:30 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOVX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $GOVX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • D. Boral Capital reiterated coverage on GeoVax Labs with a new price target

      D. Boral Capital reiterated coverage of GeoVax Labs with a rating of Buy and set a new price target of $14.00 from $18.00 previously

      4/15/25 7:54:48 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alliance Global Partners reiterated coverage on GeoVax Labs with a new price target

      Alliance Global Partners reiterated coverage of GeoVax Labs with a rating of Buy and set a new price target of $8.50 from $15.00 previously

      4/15/25 7:54:17 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alliance Global Partners initiated coverage on GeoVax Labs with a new price target

      Alliance Global Partners initiated coverage of GeoVax Labs with a rating of Buy and set a new price target of $15.00

      11/11/24 7:40:44 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Spencer John N Jr bought $9,800 worth of shares (10,000 units at $0.98), increasing direct ownership by 713% to 11,402 units (SEC Form 4)

      4 - GeoVax Labs, Inc. (0000832489) (Issuer)

      4/11/25 1:23:33 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VP, Business Development Sharkey John W. bought $5,940 worth of shares (6,000 units at $0.99), increasing direct ownership by 3,141% to 6,191 units (SEC Form 4)

      4 - GeoVax Labs, Inc. (0000832489) (Issuer)

      4/10/25 4:01:15 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President, CEO Dodd David A bought $10,800 worth of shares (10,000 units at $1.08), increasing direct ownership by 38% to 36,661 units (SEC Form 4)

      4 - GeoVax Labs, Inc. (0000832489) (Issuer)

      4/1/25 4:46:16 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOVX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Spencer John N Jr bought $9,800 worth of shares (10,000 units at $0.98), increasing direct ownership by 713% to 11,402 units (SEC Form 4)

      4 - GeoVax Labs, Inc. (0000832489) (Issuer)

      4/11/25 1:23:33 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VP, Business Development Sharkey John W. bought $5,940 worth of shares (6,000 units at $0.99), increasing direct ownership by 3,141% to 6,191 units (SEC Form 4)

      4 - GeoVax Labs, Inc. (0000832489) (Issuer)

      4/10/25 4:01:15 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President, CEO Dodd David A bought $10,800 worth of shares (10,000 units at $1.08), increasing direct ownership by 38% to 36,661 units (SEC Form 4)

      4 - GeoVax Labs, Inc. (0000832489) (Issuer)

      4/1/25 4:46:16 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOVX
    Financials

    Live finance-specific insights

    See more
    • GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update

      Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 trials expected during fourth quarter 2024 Gedeptin® on track to advance into Phase 2 clinical trial for first recurrent head and neck cancer in the first half of 2025 GEO-MVA Mpox vaccine advancing with cGMP clinical batch anticipated during fourth quarter 2024 Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced financial results for the third quarter end

      11/12/24 4:00:00 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024

      GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m. ET to provide a corporate update and discuss financial results. Conference Call Details To access the live conference call, participants may register here. The live audio webcast of the call will be available

      11/5/24 9:00:00 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update

      Awarded BARDA Project NextGen (PNG) contract to advance GeoVax's multi-antigen vaccine candidate, GEO-CM04S1, into 10,000-participant randomized, comparative Phase 2b COVID-19 vaccine study BARDA PNG award represents greater than $350 million in support of PNG GEO-CM04S1 clinical trial, including direct funding of CRO partner Allucent Multiple planned data readouts for GEO-CM04S1 throughout second half of 2024;Gedeptin® to advance into expanded Phase 2 clinical trial with activation in the first half of 2025 Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, GA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developin

      8/6/24 4:00:00 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOVX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream

      MIAMI, April 16, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 80th Emerging Growth Conference on April 16 & 17, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - TodayApril 16, 2025 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go back to t

      4/16/25 7:00:00 AM ET
      $ASBP
      $BENF
      $BNZI
      $CIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Finance: Consumer Services
      Finance
    • Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream

      MIAMI, April 15, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 81th Emerging Growth Conference on April 16 & 17, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1April 16, 2025 9:00Virtual Lobby opens.Register for the Conference. If you already register

      4/15/25 7:00:00 AM ET
      $ASBP
      $BENF
      $BNZI
      $CIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Finance: Consumer Services
      Finance
    • Presenting on the Emerging Growth Conference 80 Day 2 on March 27 Register Now

      MIAMI, March 26, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 80th Emerging Growth Conference on March 26 & 27, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - TodayMarch 26, 2025 11:00Virtual Lobby opens.Register for the Conference.  If you already registered, go back to

      3/26/25 7:00:00 AM ET
      $AEMD
      $ASPI
      $ATCH
      $BNRG
      Medical/Dental Instruments
      Health Care
      Major Chemicals
      Industrials

    $GOVX
    Leadership Updates

    Live Leadership Updates

    See more
    • GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board

      Strategic Appointment Enhances GeoVax's Leadership and Expertise in Vaccine Development ATLANTA, GA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the appointment of Teresa Lambe, PhD, OBE, FMedSci to its Scientific Advisory Board. Professor Lambe is the Calleva Head of Vaccine Immunology at the Oxford Vaccine Group within the University of Oxford and a Principal Investigator at the Pandemic Sciences Institute (PSI). She served as one of the Principal Investigators who oversaw the Oxford/AstraZeneca vaccine program; she co-designed the vacci

      8/8/24 9:00:00 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology

      Strengthening GeoVax's Team Advancing Gedeptin® Clinical Program ATLANTA, GA, Jan. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the appointment of J. Marc Pipas, M.D., to serve as the Company's Executive Medical Director, Oncology.  Kelly McKee, M.D., MPH, GeoVax Chief Medical Officer, commented, "Dr. Pipas' addition to our team represents an important step forward in the strengthening of GeoVax's organizational and operational resources to support advancement of our principal oncology asset, Gedeptin®, through clinical development

      1/8/24 9:00:00 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax

      First Woman President and CEO of MSM and Internationally Recognized Health Equity Advocate Joins in GeoVax Special Advisory Role ATLANTA, GA, Dec. 20, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today the appointment of Valerie Montgomery Rice, MD, FACOG, Morehouse School of Medicine President and CEO, as Special Advisor to the Chairman/CEO and Board of Directors of GeoVax. Dr. Montgomery Rice brings GeoVax exceptional expertise and highly recognized experience at the highest levels of healthcare leadership, patient care, biomedical resear

      12/20/22 9:00:00 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care